Bausch Health Companies Inc. (BHC)
NYSE: BHC · Real-Time Price · USD
7.44
-0.21 (-2.75%)
Jan 17, 2025, 4:00 PM EST - Market closed
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.51B in the quarter ending September 30, 2024, with 12.15% growth. This brings the company's revenue in the last twelve months to $9.47B, up 10.91% year-over-year. In the year 2023, Bausch Health Companies had annual revenue of $8.76B with 7.79% growth.
Revenue (ttm)
$9.47B
Revenue Growth
+10.91%
P/S Ratio
0.29
Revenue / Employee
$467,390
Employees
20,270
Market Cap
2.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
Dec 31, 2019 | 8.60B | 221.00M | 2.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BHC News
- 3 days ago - Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program - Accesswire
- 7 days ago - George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America - GlobeNewsWire
- 7 days ago - Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences - Business Wire
- 7 days ago - Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union - Business Wire
- 10 days ago - InflammX Therapeutics Announces Option Agreement with Bausch + Lomb - GlobeNewsWire
- 10 days ago - Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine - Business Wire
- 10 days ago - City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy - Business Wire
- 11 days ago - Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb - Business Wire